Abstract:The prognosis of patients with HCC still remains dismal. The life expectancy of HCC patients is hard to predict because of the high possibility of postoperative recurrence. Many factors, such as patient's general conditions, macroscopic tumor morphology, as well as tumor histopathology features, have been proven of prognostic significance. Female HCC patient often has a better prognosis than male patient, which might be due to the receptor of sex hormones. Younger patients often have tumors with higher invasiveness and metastatic potentials, and their survival and prognosis are worse than the older ones. Co-existing hepatitis status and hepatic functional reserve have been confirmed as risk factors for recurrence. Serum alpha-fetoprotein (AFP) is useful not only for diagnosis, but also as a prognostic indicator for HCC patients. AFP mRNA has been proposed as a predictive marker of HCC cells disseminated into the circulation and for metastatic recurrence. Many pathologic features, such as tumor size, number, capsule state, cell differentiation, venous invasion, intrahepatic spreading, and advanced pTNM stage, are the best-established risk factors for recurrence and important aspects affecting the prognosis of patients with HCC. Marked inflammatory cell infiltration in the tumor could predict a better prognosis. Clinical stage is still the most important factor influencing on the prognosis. Extratumor spreading and lymph nodal metastasis are independent predictors for poor outcome. Some new predictive systems have recently been proposed. Different strategies of treatment might have significant different effects on the patients' prognosis. To date, surgical resection is still the only potentially curative treatment for HCC, including localized postoperative recurrences. Extent of resection, blood transfusion, occlusion of porta hepatis, and blood loss affect the survival and prognosis of HCC patients. Regional therapies provide alternative ways to improve the prognosis of HCC patients who have no opportunity to receive surgical treatment or postoperative recurrence. The combination of these treatment modalities is hopeful to further improve the prognosis. The efficacies of neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy or chemoembolization in preventing recurrence and on the HCC prognosis still remain great controversy, and deserve further evaluation. Biotherapy, including IFN-alpha therapy, will play more important role in preventing recurrence and metastasis of HCC after operation.

Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy

Significance of Clinical Factors As Prognostic Indicators for Mature T-Cell Non-Hodgkin Lymphoma Patients: A Retrospective Analysis of Chinese Cases

Prognosis of Patients with Advanced Hepatocellular Carcinoma Who Failed First-Line Systemic Therapy.

Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization.

The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable

Validation of models in patients with hepatocellular carcinoma: comparison of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging system in a Chinese cohort.

Prognostic Accuracy of Staging Systems in Patients with Primary Liver Cancer Undergoing Transarterial Chemoembolization.

Comparison of Four Staging Systems in Predicting Outcomes and Guiding Option of Treatment for Patients with Hepatocellular Carcinoma

Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models

Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma

The Chinese Classification System Compared with TNM Staging in Prognosis of Patients with Primary Hepatic Carcinoma after Resection.

Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

The prognostic significance of clinical and pathological features in hepatocellular carcinoma.

Prognostic and Subgroup Analysis of 162 Patients with Barcelona Clinical Liver Cancer (BCLC) Stage B Hepatocellular Carcinoma after Hepatectomy

Clinical predictive factors of the efficacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer

Comparison of Different Clinical Staging Systems for Hepatocellular Carcinoma

A new sub-stage classification strategy for Barcelona Clinic Liver Cancer stage B patients with hepatocellular carcinoma.

Survival impact of pre-transplant local treatments in liver transplant recipients with BCLC stage A hepatocellular carcinoma

Prognostic Accuracy of Staging Systems in Patients with Primary Liver Cancer Treated with Transarterial Chemoembolization

Analysis of the Risk Factors Influencing the Prognosis of Orthotopic Liver Transplantation for Hepatocellular Carcinoma and Summary of Relevant Clinical Experience